Plasma cells dyscrasias range from indolent clinical entities (such as the monoclonal gammopathies of undetermined significance, MGUS) to true neoplasms, such as multiple myeloma (MM). The presence of plasma cells monoclonally coded to secrete a single immunoglobulin (Ig) (monoclonal component, MC) is the common feature for all entities, but other biological differences must exist between the plasma cells of MGUS and those of MM that explain the clinically different behaviour of these diseases (Barlogie et al., 1989 ).
Such differences may involve the cellular oncogenes, some of which probably play a role in transforming the B cell precursor into a MC secreting plasma cell and in originating malignancy. For example, the excretion of MC may somehow be linked with the fact that genetic material from chromosomes 11, 8 and 18 (where the proto-oncogenes bcl-2 and pim are located) is often translocated at the q32 breakpoint of chromosome 14 (Greipp, 1989) where the gene for the heavy chains of immunoglobulins is coded. Furthermore, structural changes in chromosomes 1 and 11, where Kirstenras and Harvey-ras genes are located (Gould et al., 1988) , suggest ras oncogene involvement in MM. Actually, Ha-ras is frequently activated (Neri et al., 1989) and the p21 oncoprotein (coded by Ha-ras) is overexpressed in this disease, mainly when it is in advanced phase (Tsuchiya et al., 1988) .
We have started to investigate the oncogene expression in plasma cell dyscrasias using bivariate flow cytometry (FCM) . This technique simultaneously measures the fluorescence of a monoclonal antibody (MoAb) against the protein coded by the oncogene (oncoprotein) under study and the nuclear DNA distribution (Andreeff et al., 1986; Giordano et al., 1989) , thus allowing the oncoprotein levels to be evaluated both in cell cycle phases and in distinct plasma cell populations identified according to their DNA content (Watson, 1986; Stewart, 1989) . This paper refers data obtained on the p21 oncoprotein coded by Ha-ras.
Materals and methods
Using bivariate FCM, we determined the nuclear DNA content and the p21 expression in the BM cells of five solid tumour patients (two non small cell lung, two breast and one gastric metastatic carcinomas) having no BM involvement and in those of 57 patients with plasma cell dyscrasia (28 with MGUS and 29 with MM) who underwent BM aspiration for diagnostic purposes at Clinica Medica II of the University of Pavia between January 1988 and June 1989 (Table I) .
The complete clinical, radiological and laboratory evaluation of patients with plasma cell dyscrasias was carried out according to a protocol that also require special examinations, such as P2-microglobulin and thymidine kinase level determination (Ucci et al., 1987) and BMPC proliferative activity evaluation (as the percentage labelled with in vitro BUDR and with the monoclonal antibody Ki-67). In all patients, BMPC% was counted on imprints of BM sample aspirated for FCM and p21 evaluation. Diagnosis of MM required the presence of at least two of the following three features: (a) serum and/or urine monoclonal component (MC); (b) BMPC greater than 20%; (c) osteolytic lesions on plain skeletal X-ray. Patients with a serum and/or urine MC but not fulfilling the other two criteria were considered as having MGUS.
Nineteen MM patients were studied at presentation (staging was performed according to Durie & Salmon, 1975) and ten at first relapse after having received melphalanprednisone induction and maintenance. (Krishan, 1975 Using Harvey murine sarcoma virus-transformed normal rat kidney cell lines (Ha-NRK) and the human acute T-cell leukaemia cell line Molt-4, we confirmed the specificity of the anti-Ha-ras antibody, by immunoblotting with the biotin avidin rabbit anti-sheep peroxidase system (Vector Laboratories, Burlingame, CA). The reactivity and the localisation of the antibody were also determined by fluorescence microscopy using Ha-NRK and Molt 4 cells stained according the two-step indirect immunofluorescence method described below. This antibody is especially suited for immunofluorescence and DNA-correlated flow cytometric determination, since ethanol can be used as a fixative and this generally provides the best preservation of morphology, DNA content and the most intense immunofluorescence signals. In contrast, methanol fixation is required when using the FV132-62 mouse MoAb generated against human Ha-, Ki- and N-ras p21. an interference filter of 546 ± 12 nm; a TK 590 dichromatic mirror and a K 610 barrier filter to select the emitted red fluorescence. The coefficient of variation (CV) for the GO/GI peaks was evaluated as the width at half maximum of the peak divided by the peak mean channel and the factor 2.35.
For ploidy evaluation, BM cells were analysed either alone or after they had been mixed with an aliquot of PBL, which was employed both to calibrate the instrumentation and as a diploid standard. Aneuploidy was estimated from the DNAindex (DNA-I) value, i.e. the ratio between the model channel of the GO/G1 peak of the sample under study and the modal channel of the GO/G1 peak of the reference standard. Data were collected (on a log scale but also converted to a linear scale for comparing differences between experiments) with a Consort 30 (Becton Dickinson FACS System) software program running on a dedicated Hewlett Packard computer and displayed as two-parameter contour density plots. Sequential contours represented increasing isometric equivalents of 5, 15, 30, 60, 120 and 200 cells. A total of 20,000 cells were analysed for each contour plot.
The expression of the antigens studied in the GO/GI, S and G2-M phases of the cell cycle was evaluated from the mean green fluorescence intensity of the corresponding FITClabelled antibody (inside operationally gated areas) and expressed as mean channel numbers. The same green fluorescence values for the corresponding boxes in matched control samples were also calculated. The 'net' fluorescence intensity associated with the specific staining was calculated by subtracting the nonspecific fluorescence.
Statistical analysis
The correlations between Ha-ras p21 fluorescence levels and other parameters were examined by the Student's t and x2 tests. 
Results
The results obtained are shown in Figures 1-6 . In normal and MGUS BM, the p21 oncoprotein level of the GO/GI cells was consistently low and uniform along the cell cycle (Figures 2 and 3) .
In diploid MM, the expression of p21 was more heterogeneous. The p21 level was increased (with respect to the level observed in normal and MGUS BM) in at least a part of the GO/GI cells and these high levels were maintained in the S and G2-M phase cells (Figure 4 ). In MM with both diploid and hyperdiploid plasma cells, the p21 expression was distinctly greater in the cell population with higher DNA content than in the diploid population ( Figure 5 ). The median value (in arbitrary units) of p21 expression for the hyperdiploid clone was 40.5 (range 24-57) which was higher than that found in diploid MM (median 20; range 9.5-30; P <0.005). These values were both significantly higher than those found in MGUS (median 7.5; range 3.5-11; P <0.005) and normal BM (median 6.1; range 2.0-8.3; P<0.005) (Figure 6 ). which is the common feature of both MM and MGUS. Intact proto-oncogenes normally affect cell growth and/or differentiation by producing regulatory proteins (that often share some specificity for individual cell types and cell cycle states). Alteration of oncogene structure may cause malignancy, due to overproduction, increased specific activity or deregulated synthesis of these proteins (Cooper, 1982; Bishop, 1983; Varmus, 1984) . The usual techniques for studying oncogene structure and/or function include blotting studies of DNA or of its RNA message and investigation of the biochemical function of protein products. Immunoblotting studies indicate that ras genes are probably involved in (normal) growth control (Shih & Weeks, 1984; McGrath et al., 1984; Sweet et al., 1984; Bar-Sagi, 1989) and that their alteration plays a role in causing several types of human haematological and solid tumours (Viola et al., 1985; Thoret et al., 1984; Lundy et al., 1986; Thein et al., 1986; Liu et al., 1987; Bos et al., 1987; Senn et al., 1988; Pedersen-Bjegard et al., 1988; Hirai et al., 1988) .
The technique we used evaluates the presence of an oncogene product in the cells without furnishing data either on the oncogene structure or on the product function. However, there are several advantages with this technique. Based on a MoAb against the oncogene product, bivariate FCM quantitates its expression simultaneously with DNA distribution, and this allows protein expression to be determined both in different cell cycle phases and in distinct cell populations identified according to their DNA content (Danova et al., 1988) . There have been technical difficulties in obtaining good specific fluorescences for both the MoAb against the protein and good DNA resolution, but they were overcome with the fixation-permeabilisation technique we utilised (Giordano et al., 1989) .
The median p21 expression (that was observed in all cell cycle phases) was low in normal and in MGUS BM and distinctly greater in diploid and especially in hyperdiploid MM cells (where Ha-ras has already been found to be activated frequently) (Neri et al., 1989; Tsuchiya et al., 1988) . A suggestion is that Ha-ras alteration is involved in the molecular events leading a plasma cell (already monoclonally determined to MC production in both MGUS and MM) to become a malignant cell as well.
There are several indications that plasma cells progressively change their biological properties from those of normal to MM cells. In MGUS, plasma cells are already abnormal in that they secrete a MC, but they are not malignant. The subsequent malignant transformation of MGUS into MM is a well known event. Finally, clonal selection occurs during the course of MM, with hyperdiploid clones becoming predominant (whereas they had been percentually small at diagnosis) or with the appearance of new hyperdiploid clones . Data from our study indicate that p21 expression progressively increases from MGUS to diploid, to hyperdiploid MM, thus paralleling the progressively malignant behaviour of plasma cells.
There are possible clinical implications for p21 expression studies. In our cases, the p21 expression was greater in advanced (stage III) MM and closely related with BMPC infiltration. Alpha-interferon reverses a number of transformed, tumorigenic cell lines (Brouty-Boye et al., 1985) and some reversions are associated with a significant reduction in the expression of the oncogenes implicated in the transformation process (Lin et al., 1983; Samid et al., 1984) . If we speculate that the effectiveness of this agent in MM is due to a similar mechanism, its activity may be evaluated with the FCM method we employed to detect p21 expression. Of course, the clinical meaning of both the presence and the degree of p21 expression in plasma cells dyscrasias, and especially in MM, needs large studies for final confirmations.
